<?xml version="1.0" encoding="UTF-8"?>
<p id="p0075">Anti-HDV prevalence was described among 3 groups: i) general populations, comprising people tested in community surveys, antenatal clinics, or occupational settings, students, and blood donors (unless repeat or remunerated); ii) hepatology clinic populations, comprising patients reviewed in a hepatology service, regardless of disease status; and iii) selected population groups, comprising people who inject drugs (PWID), haemodialysis recipients, men who have sex with men (MSM), commercial sex workers (CSW), and people with HCV or HIV. In sub-Saharan African countries with generalised HIV epidemics (adult prevalence &gt;1% based on UNAIDS estimates, 
 <ext-link ext-link-type="uri" xlink:href="https://aidsinfo.unaids.org/" id="intref0020" xmlns:xlink="http://www.w3.org/1999/xlink">https://aidsinfo.unaids.org/</ext-link>) people with HIV were included in the general population (note: we previously documented a lack of association between HIV status and anti-HDV prevalence in this setting).
 <xref rid="bib11" ref-type="bibr">
  <sup>11</sup>
 </xref> The definition of general populations excluded isolated or remote communities to avoid biasing the general estimates.
</p>
